NFE2L2 and prostate cancer: The carriers of both SOD2*C/C or SOD2*C/T and Nrf2*C/C genotypes were at 2.5 times greater risk of the development of prostate cancer than individuals with SOD2*T/T and Nrf2*C/A or Nrf2*A/A genotypes, regardless of the presence of the GPX1*C allele (OR = 2.48, 95% CI = 0.82–1.83, p = 0.022; OR = 2.48, 95% CI = 0.87–1.98, p = 0.021; model 1 and model 2, respectively).